Pruritus, Uremia
Conditions
Keywords
Uremic pruritis
Brief summary
To investigate using the drug gabapentin to relieve the intense pruritic sensation associated with chronic renal failure patients undergoing peritoneal dialysis.
Interventions
DRUGGabapentin
Sponsors
Pfizer
Hospital Authority, Hong Kong
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Inclusion criteria
* Adult Chinese male and female patients aged \> 18 undergoing CAPD for at least 3 months and able to read and understand Chinese * Patients experiencing moderate to severe pruritis, defined as persistent, treatment-resistant pruritis considerably impairing sleep or daytime activity. Treatment resistance is defined as no or only partial resolvement of pruritis under current anti-pruritis treatment regimens such as anti-pruritis lotions and anti-histamines. * Patients in stable clinical condition in terms of peritoneal dialysis and general health * Patients able to understand and answer the SDS questionnaire * Patients able to express the sensation of itchiness in the terms of the VAS and the SDS score * Patients who are willing to give written informed consent and to participate in and comply with the study protocol
Exclusion criteria
* Patients with a known history of pruritis or dermatologic disease antedating renal failure. * Patients with skin disease other than the usual cutaneous findings of uraemia such as xerosis or ecchymosis. * Patients under current treatment with systemic steroids * Known history of allergy to Gabapentin * Those patients already put on anti-convulsants * Unable to give written informed consent for the study * Pregnancy or female patients of child-bearing age who are unwilling to use contraception * Poor drug compliance * Known HIV positivity * Active neoplastic disease * Those who do not want to participate the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Subjective measurement of reduction in pruritus | 3 months |
Secondary
| Measure | Time frame |
|---|---|
| Tolerability of Gabapentin in CAPD patients | 3 months |
Countries
China
Contacts
Primary ContactYui Pong Siu, Dr
Outcome results
None listed